Teva Pharmaceutical Industries Ltd. ( TEVA) headquartered in Israel and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced on Dec 21 that they have entered a licensing agreement under which both companies will further develop and commercialize OGX-011, an anticancer drug that may be enlisted to treat advanced prostate cancer, lung cancer and breast cancer, and Teva will purchase shares in OncoGenex.
View the full article
0 comments:
Post a Comment